Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

661. The impact of prevention on reducing the burden of cardiovascular disease

The impact of prevention on reducing the burden of cardiovascular disease The impact of prevention on reducing the burden of cardiovascular disease The impact of prevention on reducing the burden of cardiovascular disease Kahn R, Robertson R M, Smith R, Eddy D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the potential cost-effectiveness of 11 interventions recommended to prevent cardiovascular disease (CVD) in the US population of eligible individuals aged 20 to 80 years. The authors concluded that these nationally recommended interventions prevented a high proportion of CVD, but most of them substantially increased the health care costs. The methodology was appropriate and the results were described

NHS Economic Evaluation Database.2008

662. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk (...) Greving J P, Buskens E, Koffijberg H, Algra A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of aspirin for the primary prevention of cardiovascular disease events in the Dutch population grouped

NHS Economic Evaluation Database.2008

663. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?

Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective? Grover S, Coupal L, Lowensteyn I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of hypertension and dyslipidaemia therapy for the prevention of cardiovascular disease, in asymptomatic individuals, aged 40 to 70 years. Preventive treatment appeared to be cost-effective in many eligible individuals, but the costs were high

NHS Economic Evaluation Database.2008

664. Secondary prevention of cardiovascular disease with statins. How far should we go?

Secondary prevention of cardiovascular disease with statins. How far should we go? Volumen 16. DTB Navarre. Vol 16, No 2. March - April 2008 - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : : : DTB Navarre. Vol 16, No 2. March - April 2008 DTB Navarre. Vol 16, No 2. March - April 2008 Content tools Share it Secondary prevention of cardiovascular disease with statins. How far should we go? The use of statins has shown a reduction (...) in cardiovascular morbidity and mortality in patients with coronary and atherosclerotic disease for different levels of cholesterol. Intensive treatment with high dose statins to obtain low levels of LDL-c (70-80 mg/dL or 1.8-2.0 mmol/L) in patients with stable coronary disease has shown only scarce benefits in selected patients and in composite endpoints with dubious justification. These benefits are small and there is no improvement in survival of patients with coronary disease. Intensive therapy notably

Drug and Therapeutics Bulletin of Navarre (Spain)2008

665. Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions

Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions The Norwegian Knowledge Centre for the Health Services Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation The Norwegian Knowledge Centre for the Health Services. Primary prevention of cardiovascular disease, with emphasis on pharmacological interventions. Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report number 20 - 2008. 2008 Authors' objectives To conduct a systematic review of published scientific literature on the effects of interventions for primary prevention of cardiovascular disease. This was to be used as background material

Health Technology Assessment (HTA) Database.2008

666. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis Kesselheim A S, Misono A S, Lee J L, Stedman M R, Brookhart M A, Choudhry N K, Shrank W H CRD summary This review assessed (...) the clinical evidence for the comparison of generic and brand-name drugs used in cardiovascular disease. The authors concluded that the evidence does not support the superiority of either drug class with both yielding comparable results. The review had a number of methodological shortcomings which might impinge upon the reliability of the authors' conclusions. Authors' objectives To assess the clinical evidence comparing generic and brand-name drugs used in cardiovascular disease. Searching MEDLINE, EMBASE

DARE.2008

667. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta (...) -analysis Singh S, Loke YK, Furberg CD CRD summary This review found that inhaled anticholinergics are associated with a significantly increased risk of cardiovascular death, myocardial infarction or stroke among patients with chronic obstructive pulmonary disease. The review was generally well conducted and the authors’ conclusions appear justified. Authors' objectives To evaluate the cardiovascular risks associated with the long-term use of inhaled anticholinergics in patients

DARE.2008

668. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandara N, Hathiwala S, Smith E CRD (...) summary The authors concluded that among patients with chronic kidney disease from any cause, renin angiotensin system blockade reduced myocardial infarctions, heart failure and overall cardiovascular adverse events compared with placebo. The conclusions may need to be interpreted cautiously due to the small number of studies included in the main analyses, unexplained heterogeneity and inconsistent findings across different clinical outcomes. Authors' objectives To determine the effects of renin

DARE.2008

669. A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases

A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases A meta-analysis of antibiotic use for the secondary prevention of cardiovascular diseases Song Z, Brassard P, Brophy J M CRD summary This review assessed use of antibiotics for the prevention of future cardiac events in patients with established cardiovascular disease. The authors concluded there was no evidence (...) to support this intervention. The conclusion reflected the results of the review accurately but, due to the limited search, publication bias and poor reporting of review methodology its reliability is unclear. Authors' objectives To assess the use of antibiotics for the prevention of future cardiac events in patients with established cardiovascular disease. Searching PubMed and the Cochrane Central Register of Controlled Trials were searched for studies published between January 1994 and April 2006

DARE.2008

670. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis (...) To assess the association between the combination therapy of sulfonylureas plus metformin and the risk of all-cause mortality and/or cardiovascular disease for patients with type 2 diabetes. Searching MEDLINE was searched from January 1966 to July 2007. Search terms were reported. Reference lists of included studies and relevant reviews were also screened. Study selection Observational studies that evaluated the association between the combination therapy of metformin plus sulfonylureas and the risk

DARE.2008

671. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized place

Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized place Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis (...) of randomized placebo-controlled clinical trials Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials Saha S A, Molnar J, Arora R R CRD summary The authors concluded that tissue angiotensin-converting enzyme inhibitors appear to modestly reduce the risk of myocardial infarction

DARE.2008

672. Grand Rounds: Novel Applications of Erythropoietin in Cardiovascular Disease

Grand Rounds: Novel Applications of Erythropoietin in Cardiovascular Disease Grand Rounds: “Novel Applications of Erythropoietin in Cardiovascular Disease” | Clinical Correlations Grand Rounds: “Novel Applications of Erythropoietin in Cardiovascular Disease” October 22, 2008 Commentary by Srikant Duggirala MD, PGY-2 Please also see the presented during this week’s grand rounds On Wednesday, October, 15, 2008, the NYU Department of Medicine Grand Rounds featured one of its own guest speakers (...) , Stuart Katz M.D., Professor of Medicine and Director of Heart Failure at NYU School of Medicine, with his lecture entitled “Novel Applications of Erythropoietin in Cardiovascular Disease.” Dr. Katz began his lecture with a discussion of oxygen uptake in a various individuals such as elite athletes and comparing their oxygen uptake ability to average individuals and also to heart failure patients. An elite athlete such as Lance Armstrong has an average maximum oxygen uptake 82ml/kg/min

Clinical Correlations2008

673. QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk

QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here QRISK underestimated risk of cardiovascular disease in general practice patients; Framingham score overestimated risk Article Text Clinical prediction guide QRISK underestimated risk of cardiovascular disease in general

Evidence-Based Nursing (Requires free registration)2008

675. Buflomedil reduced cardiovascular events in peripheral arterial disease

Buflomedil reduced cardiovascular events in peripheral arterial disease Buflomedil reduced cardiovascular events in peripheral arterial disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Buflomedil reduced cardiovascular events in peripheral arterial disease Article Text Therapeutics Buflomedil reduced cardiovascular events in peripheral arterial disease Statistics from Altmetric.com No Altmetric data available for this article. A Leizorovicz Dr A Leizorovicz, Service de Pharmacologie Clinique, Lyon, France; al@upcl.univ-lyon1.fr STUDY DESIGN

Evidence-Based Medicine (Requires free registration)2008

676. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. 18460663 2008 05 07 2008 05 09 2016 12 15 1538-3598 299 17 2008 May 07 JAMA JAMA Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. 2027-36 10.1001/jama.299.17.2027 Recent randomized trials among patients with preexisting (...) cardiovascular disease (CVD) have failed to support benefits of B-vitamin supplementation on cardiovascular risk. Observational data suggest benefits may be greater among women, yet women have been underrepresented in published randomized trials. To test whether a combination of folic acid, vitamin B6, and vitamin B12 lowers risk of CVD among high-risk women with and without CVD. Within an ongoing randomized trial of antioxidant vitamins, 5442 women who were US health professionals aged 42 years or older

JAMA2008 Full Text: Link to full Text with Trip Pro

677. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlle

Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlle 18555911 2008 06 16 2008 06 26 2015 06 16 1474-547X 371 9629 2008 Jun 14 Lancet (London, England) Lancet Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease (...) and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. 1999-2012 10.1016/S0140-6736(08)60868-5 Our aim was to investigate whether a nurse-coordinated multidisciplinary, family-based preventive cardiology programme could improve standards of preventive care in routine clinical practice. In a matched, cluster-randomised, controlled trial in eight European countries, six pairs of hospitals and six pairs of general practices were assigned

Lancet2008

678. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. 18997197 2008 11 12 2008 11 18 2016 12 03 1538-3598 300 18 2008 Nov 12 JAMA JAMA Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. 2123-33 10.1001/jama.2008.600 Basic research and observational studies suggest vitamin E or vitamin C may reduce the risk of cardiovascular disease. However (...) , few long-term trials have evaluated men at initially low risk of cardiovascular disease, and no previous trial in men has examined vitamin C alone in the prevention of cardiovascular disease. To evaluate whether long-term vitamin E or vitamin C supplementation decreases the risk of major cardiovascular events among men. The Physicians' Health Study II was a randomized, double-blind, placebo-controlled factorial trial of vitamin E and vitamin C that began in 1997 and continued until its scheduled

JAMA2008 Full Text: Link to full Text with Trip Pro

679. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease

How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost (...) much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease. Clinical Rehabilitation 2008; 22(10-11): 987-996 PubMedID DOI Indexing Status Subject indexing assigned by NLM MeSH Analysis of Variance; Brazil; Coronary Disease /economics /rehabilitation; Cost-Benefit Analysis /economics; Exercise Therapy /methods; Female; Heart Rate /physiology; Home Care Services, Hospital-Based

NHS Economic Evaluation Database.2008

680. Cardiovascular disease: identifying and supporting people most at risk of dying early

Cardiovascular disease: identifying and supporting people most at risk of dying early Cardio Cardiovascular disease: identifying and vascular disease: identifying and supporting people most at risk of dying supporting people most at risk of dying early early Public health guideline Published: 24 September 2008 nice.org.uk/guidance/ph15 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15) © NICE 2018. All rights

National Institute for Health and Clinical Excellence - Clinical Guidelines2008